Abstract: Interfaces for positive pressure therapy having a mask assembly, a headgear assembly and a connection port assembly are disclosed herein. The connection port assembly has a ball joint connection with the mask assembly and includes a quick release button for easily disconnecting the gases source conduit from the mask assembly. The mask assembly may include a bias flow vent that is formed separately and attached to the mask assembly. The headgear assembly encircles the rear region of the user's head and may include at least some portions that are substantially non-stretchable.

Abstract: User information is protected by providing a protective layer between a provider and a user device. A server receives a suggestion to present to the user device from a third party, such as a provider of goods or services that wants to push the suggestion to the user device. The suggestion includes a request for user information. The server then determines a likelihood that the request for user information is a necessary component of the suggestion. When the likelihood is low, the request is removed from the suggestion. When the likelihood is high, the server creates an executable computer code that includes the request. The executable computer code can be transmitted to the user device to present the suggestion to the user device without disclosing the user's information to the server.

Abstract: A test system is provided for a component of an engine. This test system includes a combustor test section and an air system. The combustor test section includes a fuel injector, an ignitor and a combustion chamber. The fuel injector is configured to direct fuel into the combustion chamber for mixing with cooled air. The ignitor is configured to ignite a mixture of the fuel and the cooled air within the combustion chamber. The air system is configured to deliver the cooled air to the combustor test section. The air system includes a compressed air source, a cryogenic cooling system and an air circuit. The cryogenic cooling system includes a cryogenic heat exchanger. The air circuit extends through the cryogenic heat exchanger and fluidly couples the compressed air source to the combustor test section.

Abstract: A spout includes a base frame fittable about a designated package pour opening surface area, an opening assembly moveably coupled to the base frame and adapted to at least partially cut/rupture/open/pierce the pour opening surface area, and a control device configured to control the opening assembly. The control device comprises at least one interaction element connected to the opening assembly, at least one control ring rotatably coupled to the base frame and at least one interaction member connected/coupled to the control ring and configured to interact with the interaction element. In use, upon rotating the control ring, the interaction member interacts with the interaction element to induce translation of a cutter of the opening assembly for controlling the opening assembly from a rest configuration to an operative configuration and an axial end portion of the interaction member is arranged within a rotation plane fixed relative to the base frame.

Abstract: An apparatus for oxygenation and/or CO2 clearance of a patient. The apparatus comprising: a flow source or a connection for a flow source for providing a gas flow, a gas flow modulator, a controller to control the gas flow. The controller is operable to: receive input relating to heart activity and/or trachea gas flow of the patient, and control the gas flow modulator to provide a varying gas flow with at least two oscillating components. One oscillating component has a frequency based on the heart activity and/or trachea flow of the patient. One oscillating component has a frequency to: promote bulk gas flow movement, or promote mixing.

Abstract: Embodiments of negative pressure wound therapy systems, apparatuses, and methods for operating the systems and apparatuses are disclosed. In some embodiments, the apparatus includes a negative pressure source, a connector port, at least one switch, and a controller. The negative pressure source is connected through the connector port to either (i) a wound dressing having a canister configured to store fluid aspirated from the wound or (ii) a wound dressing without a canister between the connector port and the wound dressing. The controller determines, based on a signal received from the at least one switch, whether the canister is positioned in the fluid flow path and adjusts one or more operational parameters of negative pressure wound therapy based on the determination. The switch is activated by the connection of either the canister or canisterless wound dressing to the apparatus.

Abstract: The invention relates to a solid pharmaceutical formulation suitable for oral administration comprising: (a) an active agent which is S-pindolol or a pharmaceutically acceptable salt thereof; (b) a starch excipient in an amount of at least 15.0% by weight relative to the total weight of the formulation; and (c) a cellulose excipient in an amount of at least 30.0% by weight relative to the total weight of the formulation. Also provided is the solid pharmaceutical formulation for use in therapy, for instance in the treatment of cachexia.

Abstract: Embodiments of negative pressure wound therapy systems, apparatuses, and methods for operating the systems and apparatuses are disclosed. In some embodiments, the apparatus includes a negative pressure source, a connector port, at least one switch, and a controller. The negative pressure source is connected through the connector port to either (i) a wound dressing having a canister configured to store fluid aspirated from the wound or (ii) a wound dressing without a canister between the connector port and the wound dressing. The controller determines, based on a signal received from the at least one switch, whether the canister is positioned in the fluid flow path and adjusts one or more operational parameters of negative pressure wound therapy based on the determination. The switch is activated by the connection of either the canister or canisterless wound dressing to the apparatus.

Abstract: A device for verifying a subject includes: a device body comprising a processor and a biometric system; wherein the biometric system comprises a first image capture device and a second image capture device, in which the first image capture device is configured to define a spatial region and the second image capture device is configured to capture an image of a subject within said spatial region, and the processor is configured to conduct an identification process on the captured image of the subject within the spatial region.

Abstract: A method to perform continuous-wave NMR measurements of nuclear magnetization at high magnetic fields, above 2.5 T, without analog down-mixing is described. An FPGA controls a digital clock pulse which is used to stimulate a resonant circuit and provide a reference signal. An algorithm determines the real portion of a resonant circuit signal near the Larmor frequency of the species of interest using only two measurements of the waveform per cycle. The FPGA automatically alters a variable capacitance to tune the resonant circuit to the Larmor frequency.

Abstract: Embodiments of negative pressure wound therapy systems, apparatuses, and methods for operating the systems and apparatuses are disclosed. In some embodiments, the apparatus includes a negative pressure source, a connector port, at least one switch, and a controller. The negative pressure source is connected through the connector port to either (i) a wound dressing having a canister configured to store fluid aspirated from the wound or (ii) a wound dressing without a canister between the connector port and the wound dressing. The controller determines, based on a signal received from the at least one switch, whether the canister is positioned in the fluid flow path and adjusts one or more operational parameters of negative pressure wound therapy based on the determination. The switch is activated by the connection of either the canister or canisterless wound dressing to the apparatus.

Abstract: Provided herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.

Abstract: Disclosed is an approach to differentiating between different particle types in samples flowing through microfluidics chips. A sample may have an initial proportion of a first cell type to a second cell type. An illuminating light source may emit a coherent light at the sample, and light leaving the chip in a first direction may be detected using a first light detector, and light leaving the chip in a second direction (e.g., orthogonal to the first direction) may be detected using a second light detector. The detected light may be fluorescence. An orientational feature of a plurality of cells in the sample may be determined based on the light detected by the detectors. Based on the orientational features and the detected light, a biasing operation may be performed for each cell in the sample to obtain a modified proportion of cell types in the sample.

Abstract: Provided herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.

Abstract: Embodiments of negative pressure wound therapy systems, apparatuses, and methods for operating the systems and apparatuses are disclosed. In some embodiments, the apparatus includes a negative pressure source, a connector port, at least one switch, and a controller. The negative pressure source is connected through the connector port to either (i) a wound dressing having a canister configured to store fluid aspirated from the wound or (ii) a wound dressing without a canister between the connector port and the wound dressing. The controller determines, based on a signal received from the at least one switch, whether the canister is positioned in the fluid flow path and adjusts one or more operational parameters of negative pressure wound therapy based on the determination. The switch is activated by the connection of either the canister or canisterless wound dressing to the apparatus.

Abstract: A spout includes a base frame fittable about a designated package pour opening surface area, an opening assembly moveably coupled to the base frame and adapted to at least partially cut/rupture/open/pierce the pour opening surface area, and a control device configured to control the opening assembly. The control device comprises at least one interaction element connected to the opening assembly, at least one control ring rotatably coupled to the base frame and at least one interaction member connected/coupled to the control ring and configured to interact with the interaction element. In use, upon rotating the control ring, the interaction member interacts with the interaction element to induce translation of a cutter of the opening assembly for controlling the opening assembly from a rest configuration to an operative configuration and an axial end portion of the interaction member is arranged within a rotation plane fixed relative to the base frame.

Abstract: A package assembly (300, 400, 500) comprising a package (100, 302) arranged to hold a food product, wherein the package (100,302) comprises a rear section (140) provided with a longitudinal seal (LS), and an exoskeleton (308, 402, 502, 600, 700, 800, 900, 1000, 1100, 1200, 1300) attached to the rear section (140) of the package (100,302) such that an improved robustness is achieved and that the longitudinal seal (LS) is protected.

Abstract: Described herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.

Abstract: Provided herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.